Granules India Q1 Revenue Hits 14.77 Bln Rupees

HYDERABAD — Major Indian pharmaceutical manufacturer Granules India Limited announced its consolidated financial performance for the first quarter, posting a total revenue from operations of 14.77 billion rupees, according to official corporate filings released in Hyderabad. Alongside the top-line performance, the company delivered a solid net profit of 1.8 billion rupees, signaling resilience and continued execution capability across core global markets.

The earnings report highlights steady demand momentum within the company’s vertically integrated business model, encompassing active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs) targeted at regulated markets including North America and Europe.

Operational Performance and Segment Growth

According to regulatory disclosures filed with stock exchanges, the revenue expansion was supported by consistent volume growth and robust pipeline execution across key therapeutic categories. Management noted that continuous improvements in manufacturing efficiency at key production plants helped mitigate external cost pressures, ensuring healthy operational margins.

The company's strategic focus on expanding its high-value product portfolios, coupled with ongoing facility remediation programs and strict adherence to global regulatory compliances, continues to underpin its competitive standing in the international pharmaceutical landscape.

Official Sources Section

Financial figures, operational metrics, and governance disclosures were formally communicated through statutory filings submitted to regulatory authorities.

"According to officials, the consolidated financial statements reflect steady business execution and stable demand across core international regulatory markets during the quarter."

Further financial breakdowns and investor presentations can be accessed via BSE Limited, the National Stock Exchange of India, and the Ministry of Finance.

Why It Matters

For investors and market analysts, Granules India’s consistent revenue and profit figures provide clear visibility into the firm's operational stability amid shifting macroeconomic conditions. For healthcare consumers and global partners, sustained financial health ensures uninterrupted production and supply of essential, high-quality medicines across international distribution networks.

Key Facts at a Glance

• Total Consolidated Revenue (Q1): 14.77 billion rupees.

• Consolidated Net Profit (Q1): 1.8 billion rupees.

• Core Sectors: Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages.

• Reporting Entity: Granules India Limited, headquartered in Hyderabad.

Frequently Asked Questions

What was Granules India's total consolidated revenue for the quarter?

The company reported a consolidated total revenue from operations of 14.77 billion rupees for the quarter under review.

What was the consolidated profit recorded by the company?

Granules India posted a consolidated net profit of 1.8 billion rupees for the quarter.

Which core segments drive Granules India's business model?

The company operates primarily across three verticals: active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs).

Where can official financial filings for Granules India be viewed?

Official quarterly financial results and regulatory disclosures are publicly available on BSE Limited, the National Stock Exchange of India, and the company's investor portal.

Source: BSE Limited, National Stock Exchange of India, Ministry of Finance, Company Regulatory Disclosures